The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017
Open accessAbstract
For many years, the diagnosis and classification of gliomas have been based on histology. Although studies including large populations of patients demonstrated the prognostic value of histologic phenotype, variability in outcomes within histologic groups limited the utility of this system. Nonetheless, histology was the only proven and widely accessible tool available at the time, thus it was used for clinical trial entry criteria, and therefore determined the recommended treatment options. Research to identify molecular changes that underlie glioma progression has led to the discovery of molecular features that have greater diagnostic and prognostic value than histology. Analyses of these molecular markers across populations from randomized clinical trials have shown that some of these markers are also predictive of response to specific types of treatment, which has prompted significant changes to the recommended treatment options for grade III (anaplastic) gliomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Baumert, B. G., Hegi, M. E., van den Bent, M. J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., Brandes, A. A., Kantor, G., Taphoorn, M. J. B., Hassel, M. B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30313-8 · Cited by 495
Olar, A., Wani, K. M., Alfaro-Munoz, K. D., Heathcock, L. E., van Thuijl, H. F., Gilbert, M. R., Armstrong, T. S., Sulman, E. P., Cahill, D. P., Vera-Bolanos, E., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1398-z · Cited by 354
Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading
Giannini, C., Scheithauer, B. W., Weaver, A. L., Burger, P. C., Kros, J. M., Mork, S., Graeber, M. B., Bauserman, S., Buckner, J. C., Burton, J., et al. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.3.248 · Cited by 219
Dubbink, H. J., Atmodimedjo, P. N., Kros, J. M., French, P. J., Sanson, M., Idbaih, A., Wesseling, P., Enting, R., Spliet, W., Tijssen, C., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov182 · Cited by 163
Cited by
Immunotherapy for glioma: Current management and future application
Xu, S., Tang, L., Li, X., Fan, F., & Liu, Z. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.002 · Cited by 746
Trends in primary central nervous system lymphoma incidence and survival in the U.S.
Shiels, M. S., Pfeiffer, R. M., Besson, C., Clarke, C. A., Morton, L. M., Nogueira, L., Pawlish, K., Yanik, E. L., Suneja, G., & Engels, E. A. (2016) · British Journal of Haematology · doi:10.1111/bjh.14073 · Cited by 269
Lehrer, E. J., Peterson, J., Brown, P. D., Sheehan, J. P., Quiñones-Hinojosa, A., Zaorsky, N. G., & Trifiletti, D. M. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.08.025 · Cited by 264
Lehrer, E. J., Peterson, J. L., Zaorsky, N. G., Brown, P. D., Sahgal, A., Chiang, V. L., Chao, S. T., Sheehan, J. P., & Trifiletti, D. M. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.10.038 · Cited by 263
Metadata
- Authors
- Nabors, L. B., Portnow, J., Ammirati, M., Baehring, J., Brem, H., Butowski, N., Fenstermaker, R. A., Forsyth, P., Hattangadi-Gluth, J., Holdhoff, M., Howard, S., Junck, L., Kaley, T., Kumthekar, P., Loeffler, J. S., Moots, P. L., Mrugala, M. M., Nagpal, S., Pandey, M., Parney, I., Peters, K., Puduvalli, V. K., Ragsdale, J., Rockhill, J., Rogers, L., Rusthoven, C., Shonka, N., Shrieve, D. C., Sills, A. K., Swinnen, L. J., Tsien, C., Weiss, S., Wen, P. Y., Willmarth, N., Bergman, M. A., & Engh, A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2017-11
- Volume
- 15
- Issue
- 11
- Pages
- 1331-1345
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2183991412
- Cited by
- 231
- References
- 5
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.